AMAdam Maciejewski

Adam Maciejewski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adam Maciejewski has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic and Predictive Significance of Selected Gene Mutations in Pancreatic and Intestinal Neuroendocrine Tumors

    by Jan Musiałkiewicz, Bartłomiej Budny, Aleksandra Anioła, Adam Maciejewski, Paweł Komarnicki, Joanna Maciejewska, Paweł Gut, Marek Ruchała

    Neuroendocrine tumors (NETs) constitute a heterogeneous and predominantly malignant group of neuroendocrine neoplasms that arise from endocrine cells dispersed throughout the body. Their clinical presentation, biological behavior, prognosis, and therapeutic management vary considerably depending on the primary tumor location and hormonal activity. Despite substantial progress in understanding the biology of NETs, identifying reliable molecular biomarkers for diagnosis, prognosis, and prediction of treatment response remains a major challenge. Increasing attention has therefore been devoted to the molecular characterization of NETs, with particular focus on recurrent genetic alterations that may contribute to tumor initiation and progression. In this review, we summarize current knowledge and recent findings referring to certain genes involved in the tumorigenesis of pancreatic and intestinal neuroendocrine tumors. We chose the genes based on data from the COSMIC (Catalogue of Somatic Mutations in Cancer) database, which compiles somatic mutations identified across numerous human cancers. We outline the biological functions of these changes and discuss their potential prognostic and predictive role as molecular markers. We also discuss their clinical relevance in both sporadic and familial forms of NETs, alongside their implications for future research and personalized management strategies.

  • Open Access

    Serum Visfatin/eNAMPT as a Biomarker in Pancreatic and Small Intestine Neuroendocrine Tumors: A Cross-Sectional Study and Future Perspectives

    by Paweł Komarnicki, Adam Maciejewski, Jan Musiałkiewicz, Michalina Czupińska, George Mastorakos, Marek Ruchała, Paweł Gut

    Background : Neuroendocrine tumors (NETs) remain a problematic area in endocrine oncology due to their non-specific symptoms and lack of reliable biomarkers. Visfatin/eNAMPT’s involvement in tumorigenesis has been described in several malignancies. In NETs, NAMPT inhibition was explored as a potential therapeutic option; however, serum visfatin and its role as a biomarker have not been studied. Objectives: We aimed to measure serum visfatin concentrations in NETs and evaluate visfatin’s potential as a diagnostic biomarker. Methods: We conducted a single-center, cross-sectional study of 77 patients with NETs (33 pancreatic and 44 small intestinal) and 29 controls. Patient demographics, tumor characteristics, and clinical data were analyzed, and serum visfatin levels were measured using ELISA. Statistical analyses were performed in Python, including Mann–Whitney U and Kruskal–Wallis tests, Spearman’s correlation, multiple linear regression, and ROC curve analysis. Results: Serum visfatin was higher in NETs compared to controls (median [IQR]: 6.94 [2.11–236.17] vs. 1.59 [1.1–9.24] ng/mL, p = 0.004). ROC curves showed moderate diagnostic performance (AUC = 0.68), with concentrations above 2.11 ng/mL achieving 75.3% sensitivity and 58.6% specificity. In NETs, visfatin did not differ based on WHO grade (G1/G2, p = 0.31), primary site (pancreas/small intestine, p = 0.95), sex (p = 0.89), age (p = 0.13), and when stratified by primary site and grade (p = 0.18). Multiple linear regression confirmed no association between visfatin and the study variables (R-squared = 0.036, all p > 0.2). Conclusions: This is the first study examining serum visfatin as a diagnostic biomarker in NETs. Visfatin concentrations show moderate discriminatory ability between NETs and controls, independent of tumor and clinical characteristics. Further research should involve larger cohorts and comparisons to established biomarkers.


  • Open Access

    Exon 11 Polymorphism (rs1126797) in the Thyroid Peroxidase (TPO) Gene Among Caucasian Polish Patients with Autoimmune Thyroiditis: A Short Communication

    by Katarzyna Lacka, Adam Maciejewski, Aleksandra M. Łącka, Waldemar Herman, Jan K. Lacki, Ryszard Żaba, Michał J. Kowalczyk

    Autoimmune thyroiditis (AIT), or Hashimoto’s thyroiditis, is one of the most prevalent autoimmune endocrine disorders. Its pathogenesis is complex and involves both environmental and genetic factors, yet it remains incompletely understood. Among the genetic contributors, thyroid-specific genes, including thyroid peroxidase (TPO) and thyroglobulin (Tg), have been implicated. The aim of this study was to investigate the potential association between the TPO gene single nucleotide polymorphism rs1126797, located in exon 11, and the risk of developing AIT in a Caucasian Polish population. To date, this SNP has not been studied in European cohorts, prompting us to explore its role following prior assessments in other ethnic groups. A total of 234 patients diagnosed with AIT and 132 healthy control subjects were enrolled. Genotyping of rs1126797 was performed using the TaqMan SNP Genotyping Assay. Allele and genotype frequencies were compared between groups, and associations with clinical parameters, including thyroid volume, were analyzed. No statistically significant differences in allele or genotype frequencies of rs1126797 were observed between AIT patients and healthy controls. However, a weak, significant trend was noted, suggesting a possible association between rs1126797 genotypes and thyroid volume in patients with AIT. Our findings do not support a significant role of the TPO rs1126797 polymorphism in conferring susceptibility to autoimmune thyroiditis in the studied Caucasian Polish population. However, the observed trend in thyroid volume among AIT patients with different rs1126797 genotypes warrants further investigation. Future studies involving larger and ethnically diverse cohorts are needed to validate these findings.


  • Open Access

    Rationale for Testing TP53 Mutations in Thyroid Cancer—Original Data and Meta-Analysis

    by Katarzyna Lacka, Adam Maciejewski, Piotr Tyburski, Ewa Manuszewska-Jopek, Przemysław Majewski, Barbara Więckowska

    The p53 protein is a tumor-suppressing transcription factor that is critical in tumorigenesis. While TP53 mutations are rare in differentiated thyroid cancer (DTC), they are significantly more common in anaplastic thyroid cancer (ATC). This study presents original results and a meta-analysis reevaluating the prognostic value of TP53 mutations in thyroid cancer, including surrogate markers such as immunohistochemical p53 expression and serum p53-Abs levels. TP53 mutations were analyzed using SSSP and direct sequencing in a DTC group (15 patients), an ATC group (3 patients), and a control group (25 patients). The immunohistochemical p53 expression was assessed in tissue samples. A meta-analysis of 14 eligible studies identified through the PubMed, Scopus, Google Scholar, and Cochrane databases was conducted. Our results showed TP53 mutations in all ATC cases, 6.67% of DTC cases (1 out of 15), and none in the control group. Immunohistochemical p53 overexpression was observed in 4 out of 15 DTC (26.67%) and all ATC cases but absent in controls. A meta-analysis confirmed that TP53 mutations are significantly more frequent in ATC than controls (OR 8.95; 95% CI: 1.36–58.70; p = 0.02) but not in DTC vs. controls (OR 1.87; 95% CI: 0.53–6.58; p = 0.33). p53 overexpression was significantly higher in both DTC and ATC vs. controls (OR 7.99; 95% CI: 5.11–12.51; p < 0.01 and OR 64.37; 95% CI: 27.28–151.89; p < 0.01, respectively). The serum p53-Abs positivity was also elevated in patients with PTC vs. controls (OR 2.07; 95% CI: 1.24–3.47; p < 0.01). TP53 mutations are frequent events in the pathogenesis of ATC. In DTC, further prospective studies are needed to determine the prognostic value of TP53 mutations and related surrogate markers (immunohistochemical p53 expression, p53-Abs positivity).


  • Open Access

    Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach

    by Paweł Komarnicki, Paweł Gut, Maja Cieślewicz, Jan Musiałkiewicz, Adam Maciejewski, Michalina Czupińska, George Mastorakos, Marek Ruchała

    Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic, due to their diversity and the lack of suitable biomarkers. Multianalyte assays and the shift to an omics-based approach improve on the conventional single-analyte strategy, albeit with their own drawbacks. We explored the potential of serum β-hCG as a biomarker for NETs and discussed its role in disease monitoring. We recruited 40 patients with non-functioning pancreatic NETs, all with liver metastases. Serum β-hCG concentrations were measured at 3-month intervals over 48 months. We performed a comparative and a repeated measures analysis of β-hCG depending on WHO grade (G1, G2), liver tumor burden (LTB; below 10%, 10–25%), and RECIST 1.1. (stable disease, progressive disease). Patients with progressive disease (p < 0.001), 10–25% LTB (p < 0.001) and WHO Grade 2 (p < 0.001) displayed higher β-hCG concentrations. Throughout the study, β-hCG concentrations consistently increased across the entire cohort. Delta β-hCG during the study period was greater in patients with 10–25% LTB (p < 0.001), progressive disease (p < 0.001), and G2 (p = 0.003). Serum β-hCG correlates with established indicators of malignancy and disease progression in metastatic NETs, supporting further studies as a monitoring and prognostic biomarker. Despite promising results from novel biomarkers, there is still a place for single-analyte assays in NETs.


  • Open Access

    Is There a Link between Thyroid Peroxidase Gene Promoter Polymorphisms and Autoimmune Thyroiditis in the Polish Population?

    by Katarzyna Lacka, Adam Maciejewski, Piotr Jarecki, Waldemar Herman, Jan K. Lacki, Ryszard Żaba, Michał J. Kowalczyk

    (1) Autoimmune thyroiditis (AIT) is the most common cause of primary hypothyroidism and one of the most frequent organ-specific autoimmune diseases. Its pathogenesis is polygenic and still requires further research. The aim of the study was to assess, for the first time in the Caucasian population, the role of selected TPO gene promoter polymorphisms (rs2071399 G/A, rs2071400C/T, rs2071402 A/G, and rs2071403 A/G) in the development of AIT. A total of 237 patients diagnosed with AIT and 130 healthy controls were genotyped for four TPO gene polymorphisms, and the results were statistically analyzed to check for the role of these polymorphisms. There were no significant differences in the genotype and allele frequencies of the studied TPO gene promoter polymorphisms between patients and controls (p > 0.05). The haplotype distribution (rs2071400–rs2071402–rs2071403) between the two studied groups was similar for the most common variants (CGA, CAG, TGG). Only a rare haplotype (CGG) occurred more frequently among patients compared to controls (p = 0.04). The studied TPO gene promoter polymorphisms did not show an association with susceptibility to AIT in the Caucasian Polish population, contrary to the results in Japanese patients.


  • Open Access

    Effects of Isoflavonoid and Vitamin D Synergism on Bone Mineral Density—A Systematic and Critical Review

    by Miłosz Miedziaszczyk, Adam Maciejewski, Ilona Idasiak-Piechocka, Marek Karczewski, Katarzyna Lacka

    Phytoestrogens are non-steroidal plant compounds, which bind to α and β estrogen receptors, thereby causing specific effects. The best-known group of phytoestrogens are flavonoids, including isoflavonoids—genistein and daidzein. They play a role in the metabolism of bone tissue, improving its density and preventing bone loss, which contributes to reducing the risk of fractures. Vitamin D is found in the form of cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) and is traditionally recognized as a regulator of bone metabolism. The aim of this review was to evaluate the synergistic effect of isoflavonoids and vitamin D on bone mineral density (BMD). The MEDLINE (PubMed), Scopus and Cochrane databases were searched independently by two authors. The search strategy included controlled vocabulary and keywords. Reference publications did not provide consistent data regarding the synergistic effect of isoflavonoids on BMD. Some studies demonstrated a positive synergistic effect of these compounds, whereas in others, the authors did not observe any significant differences. Therefore, further research on the synergism of isoflavonoids and vitamin D may contribute to a significant progress in the prevention and treatment of osteoporosis.


  • Open Access

    Vitamin D-Related Genes and Thyroid Cancer—A Systematic Review

    by Adam Maciejewski, Katarzyna Lacka

    Vitamin D, formerly known for its role in calcium-phosphorus homeostasis, was shown to exert a broad influence on immunity and on differentiation and proliferation processes in the last few years. In the field of endocrinology, there is proof of the potential role of vitamin D and vitamin D-related genes in the pathogenesis of thyroid cancer—the most prevalent endocrine malignancy. Therefore, the study aimed to systematically review the publications on the association between vitamin D-related gene variants (polymorphisms, mutations, etc.) and thyroid cancer. PubMed, EMBASE, Scopus, and Web of Science electronic databases were searched for relevant studies. A total of ten studies were found that met the inclusion criteria. Six vitamin D-related genes were analyzed (VDR—vitamin D receptor, CYP2R1—cytochrome P450 family 2 subfamily R member 1, CYP24A1—cytochrome P450 family 24 subfamily A member 1, CYP27B1—cytochrome P450 family 27 subfamily B member 1, DHCR7—7-dehydrocholesterol reductase and CUBN—cubilin). Moreover, a meta-analysis was conducted to summarize the data from the studies on VDR polymorphisms (rs2228570/FokI, rs1544410/BsmI, rs7975232/ApaI and rs731236/TaqI). Some associations between thyroid cancer risk (VDR, CYP24A1, DHCR7) or the clinical course of the disease (VDR) and vitamin D-related gene polymorphisms were described in the literature. However, these results seem inconclusive and need validation. A meta-analysis of the five studies of common VDR polymorphisms did not confirm their association with increased susceptibility to differentiated thyroid cancer. Further efforts are necessary to improve our understanding of thyroid cancer pathogenesis and implement targeted therapies for refractory cases.


  • Combined large-cell neuroendocrine carcinoma and atypical carcinoid of the thymus presenting as ectopic Cushing’s syndrome

    by Adam Maciejewski, Paweł Gut, Piotr Stajgis, Kosma Woliński, Paweł Komarnicki, Marek Ruchała

    DOI: 10.20452/pamw.16312, Published online: August 04, 2022, Authors: Adam Maciejewski, Paweł Gut, Piotr Stajgis, Kosma Woliński, Paweł Komarnicki, Marek Ruchała


  • Open Access

    Effect of Various Exercise Regimens on Selected Exercise-Induced Cytokines in Healthy People

    by Remigiusz Domin, Daniela Dadej, Michał Pytka, Ariadna Zybek-Kocik, Marek Ruchała, Przemysław Guzik

    Different forms of physical activity—endurance, resistance or dynamic power—stimulate cytokine release from various tissues to the bloodstream. Receptors for exercise-induced cytokines are present in muscle tissue, adipose tissue, liver, brain, bones, cardiovascular system, immune system, pancreas, and skin. They have autocrine, paracrine and endocrine activities. Many of them regulate the myocyte growth and differentiation necessary for muscle hypertrophy and myogenesis. They also modify energy homeostasis, lipid, carbohydrate, and protein metabolism, regulate inflammation and exchange information (crosstalk) between remote organs. So far, interleukin 6 and irisin have been the best studied exercise-induced cytokines. However, many more can be grouped into myokines, hepatokines and adipomyokines. This review focuses on the less known exercise-induced cytokines such as myostatin, follistatin, decorin, brain-derived neurotrophic factor, fibroblast growth factor 21 and interleukin 15, and their relation to various forms of exercise, i.e., acute vs. chronic, regular training in healthy people.